DSSG Group: Lung

Resected Stage II, IIIA,IIIB (N2) Non-Small Cell Lung Cancer.

The purpose of the study is to measure which of the arms of patients (i.e. patient on the Adjuvant V940 (mRNA-4157) Plus Pembrolizumab or Adjuvant Placebo Plus Pembrolizumab) has a better disease free survival outcome (time from starting the study to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, as assessed by the investigator, or death due to any cause).

The study will also measure other parameters such as the overall survival of the patients, lung cancer specific survival, if patients experience any adverse events and patients Quality of Life while participating.

Lung caner patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status[Cohort 1] or Elderly (≥70 years) [Cohort 2]

The purpose of the trial is to assess the clinical efficacy of adagrasib treatment in patients with KRASG12C-mutant NSCLC, in patients who are elderly (≥70 years) or those with poor performance status (ECOG PS=2).

Non-Small Cell Lung Cancer

The main purpose of this study is see if EBC(Exhaled Breath Condensate) can be used to check for biomarkers which are associated with a radiologic response to chemoimmunotherapy for patients with advanced NSCLC

Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

This Phase 2 study will evaluate the efficacy and safety of MRTX849 on its own and in combination with pembrolizumab.

The Phase 3 portion of the study compares the efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab plus chemotherapy

inoperable, early stage, high-risk ultracentrally located lung tumours.

The purpose of the study is to determine the safety of the radiation therapy treatment regimen in terms of side effects experienced within one year after treatment which are related to the radiation therapy.